OneSource Specialty Pharma reported a 12% YoY revenue increase in Q2FY26, reaching ₹3,758 million. EBITDA grew by 37% YoY to ₹1,065 million, with margin expansion of approximately 506 bps. Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9. The company is raising its FY28 revenue outlook to $500m+ following a proposed acquisition.
Q2FY26 Financial Performance
OneSource Specialty Pharma Limited announced its consolidated financial results for Q2FY26, ended September 30, 2025. Key highlights include:
- Revenues: ₹3,758 million, up 12% YoY
- EBITDA: Grew 37% YoY to ₹1,065 million
- EBITDA Margin: 28%, an expansion of approximately 506 bps YoY
- Adjusted PAT: Stood at ₹449 million with adjusted EPS of ₹3.9
H1FY26 Performance Overview
The company also reported on its performance for the first half of fiscal year 2026:
- Revenues: ₹7,030 million, up 12% YoY
- EBITDA: ₹1,950 million, up 37% YoY
Strategic Developments
The recently announced proposed acquisition of Poland and Brooks delivered a strong first half with combined revenue of $29 million and EBITDA of $11 million, translating into healthy margins of 38%.
Revised Outlook
Following the recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India, OneSource is raising its FY28 revenue outlook to $500m+.
Source: BSE
